top of page


In this issue of GOLD, we shine a light on the top news stories from the pharmaceutical industry over the past few months. The COVID-19 pandemic continues to dominate news headlines, with vaccine trials gaining momentum and showing considerable promise. Alongside this progression, we are still seeing novel drug approvals, major acquisitions, and an increasing number of collaborations taking place.

17 August

Sanofi acquires Principia Biopharma Inc., solidifying their presence in allergy and autoimmune disease R&D.

25 August

In a monumental milestone, Nigeria becomes the last country in Africa to eradicate wild polio.

01 September

BMS’ oral tablet, Onureg®, gains US approval for adults with acute myeloid leukaemia.

02 September

Novo Nordisk launches the world’s first oral GLP-1 receptor for treatment of type 2 diabetes.

08 September

MSD announce the success of Gefapixant in decreasing the frequency of persistent, unexplained, or treatment-resistant coughs.

09 September

Patrik Jonsson is named as new Chief Customer Officer, Senior Vice President, and President of Lilly USA.

13 September

AstraZeneca and Oxford University resume clinical trials for their COVID-19 vaccine candidate.

14 September

Gilead acquires Immunomedics for $21 billion, adding triple-negative breast cancer drug, Trodelvy, to its portfolio .

18 September

Sanofi and GSK commit with European Commission to provide 300 million COVID-19 vaccine doses to the EU.

22 September

Roche acquires Irish biotech firm Inflazome for $449 million in a bid to increase its offering of NLRP3 inhibitors.

01 October

NICE backs Sandoz’s opioid-induced constipation drug, Rizmoic, which will be made available on the NHS in UK.

06 October

Merck enter agreement with Novartis to launch an osteoarthritis clinical-stage programme.

Read next

Subscribe to GOLD


Sign up to receive a weekly roundup of our latest articles, interviews and more 

bottom of page